Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Decitabine Followed by Neoadjuvant Chemotherapy in Locally Advanced HER2-Negative Breast Cancer
NCT02957968Phase 2Active, not recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2017
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and decitabine in breast cancer (3 cohorts), sponsored by Virginia Commonwealth University. Primary endpoint: Percentage of Increase in Tumor and Stroma With Infiltrating Lymphocytes (TIL). Started Jan 2017; status: active, not recruiting.
02
Drugs
pembrolizumabdecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02957968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957968.